Henry Ford Hospital
- Type
- Teaching hospital
- Where
- Detroit, MI
- Medicare CCN
- 230053
- Received
- $16,355,554 in 1,727 records, 2024 ($3,233,636 general, $13,121,918 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: HENRY FORD HOSPITAL Fuzzy (name and state)
- Patent assignee: Henry Ford Hospital Fuzzy (name and state)
- Trademark owner: HENRY FORD HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 209 | $3,233,636 |
| 2024 | Research payment | 1,518 | $13,121,918 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 1,518 | $13,121,918 |
| Grant | 37 | $2,253,039 |
| Space rental or facility fees (teaching hospital only) | 100 | $361,000 |
| Consulting Fee | 5 | $152,088 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 28 | $147,487 |
| Education | 7 | $126,000 |
| Royalty or License | 3 | $84,594 |
| Long term medical supply or device loan | 13 | $54,733 |
| Charitable Contribution | 1 | $25,000 |
| Debt forgiveness | 7 | $20,635 |
| Travel and Lodging | 6 | $8,822 |
| Food and Beverage | 2 | $234 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | Merck Sharp & Dohme LLC | $211,347 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $83,359 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab MK-3475 in | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $74,205 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin | 2024 |
| 2024-12-31 | Vasc-Alert LLC | $59,094 | Royalty or License (4 payments) | Cash or cash equivalent | Vasc-Alert Device, hemodialysis | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $47,387 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $40,382 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $34,344 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab MK-3475 in | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $33,772 | Research payment | In-kind items and services | Drug, ONCOLOGY | A Phase 3, Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participant | 2024 |
| 2024-12-31 | PFIZER INC. | $26,676 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $23,031 | Research payment | In-kind items and services | Drug, INFECTIOUS DISEASE | A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, a | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $22,417 | Research payment | In-kind items and services | LAGEVRIO Biological, INFECTIOUS DISEASE | A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupirav | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $18,589 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $15,656 | Research payment | In-kind items and services | Drug, ONCOLOGY | A Phase 3 Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $14,006 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2024 |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $13,043 | Research payment | In-kind items and services | ENHERTU Biological, Oncology | Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in | 2024 |
| 2024-12-31 | NX Development Corp. | $11,570 | Research payment | Cash or cash equivalent | MEN-301 | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $10,605 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo controlled Study to Evaluate the Safety and Efficacy of Pemetrexed Platinum Chemotherapy | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $10,477 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $10,385 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $10,073 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination wit | 2024 |
| 2024-12-31 | ABBVIE INC. | $9,733 | Research payment | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | M23-716 Rinvoq Ph 3 Alopecia Areata | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $9,336 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab MK-3475 Versus Placebo in Participants wit | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $7,982 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Ad | 2024 |
| 2024-12-31 | Stryker Corporation | $7,523 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Merck Sharp & Dohme LLC | $6,915 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized Study of Lenvatinib in Combination with Pembrolizumab Versus Standard of Care in Participants with | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $6,728 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2024 |
| 2024-12-31 | Siemens Medical Solutions USA, Inc. | $6,111 | Research payment | Cash or cash equivalent | Varian Ethos Treatment Planning Device, Oncology | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $5,383 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $4,678 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Trial of Pembrolizumab MK-3475 in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Partici | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $4,126 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Ad | 2024 |
| 2024-12-31 | ABBVIE INC. | $3,053 | Research payment | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | M19-044 Rinvoq Phase 3 Vitiligo | 2024 |
| 2024-12-31 | Intuitive Surgical, Inc. | $3,000 | Long term medical supply or device loan | In-kind items and services | ION Device, SURGERY | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $2,262 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2024 |
| 2024-12-31 | AstraZeneca UK Limited | $2,080 | Research payment | In-kind items and services | IMFINZI Biological, Oncology | a phase IIIb single arm,open label,multicentre sudy of durvalumab and tremelimumab as first line treatment in participan | 2024 |
| 2024-12-31 | Stryker Corporation | $2,065 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $2,065 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $1,770 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as | 2024 |
| 2024-12-31 | Stryker Corporation | $1,627 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $1,579 | Research payment | In-kind items and services | A Randomised,Double Blind,Placebo Controlled,Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Par | 2024 | |
| 2024-12-31 | Stryker Corporation | $1,146 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Stryker Corporation | $1,059 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Merck Sharp & Dohme LLC | $972 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as | 2024 |
| 2024-12-31 | Stryker Corporation | $958 | Long term medical supply or device loan | In-kind items and services | RemB Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | ABBVIE INC. | $875 | Research payment | In-kind items and services | A Phase I Study of ABBV-011 as a Single-Agent and in Combination with Budigalimab (ABBV-181) in Subjects with Relapsed o | 2024 | |
| 2024-12-31 | ABBVIE INC. | $788 | Research payment | In-kind items and services | M23-385 ABBV-706 Ph 1 2L-4L SCLC | 2024 | |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $735 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Pla | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $719 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin a | 2024 |
| 2024-12-31 | Stryker Corporation | $338 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Merck Sharp & Dohme LLC | $189 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $71 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Single-arm, Open-label Monotherapy Clinical Trial of Pembrolizumab MK-3475 in Locally Advanced,Metastatic Ren | 2024 |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $58 | Research payment | In-kind items and services | LOKELMA Drug, Cardiovascular and Metabolism | Cardiovascular Renal and Metabolism Lokelma Hyperkalemia | 2024 |
| 2024-12-31 | Vitrolife Inc. | $49 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Merck Sharp & Dohme LLC | $29 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Trial to Investigate Genetic Markers of Immune Response to Pembrolizumab MK-3475, SCH 900475 Combined with Ch | 2024 |
| 2024-12-31 | Stryker Corporation | $17 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-30 | Eli Lilly and Company | $2,365 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION | 2024 | |
| 2024-12-30 | Janssen Research & Development, LLC | $337 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2024 |
| 2024-12-28 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | CIBINQO Drug, Inflammation & Immunology | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPI | 2024 |
| 2024-12-27 | Merck Sharp & Dohme LLC | $117,458 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2024 |
| 2024-12-27 | SpringWorks Therapeutics, Inc. | $11,582 | Research payment | Cash or cash equivalent | MEK-NF-201 | 2024 | |
| 2024-12-27 | Ethicon Endo-Surgery Inc. | $4,000 | Research payment | Cash or cash equivalent | Echelon; Endopath Device, Endo-Mechanical | A Multi-Center Evaluation of the ECHELONT 3000 (Next Generation Powered Stapler) in Laparoscopic Sleeve Gastrectomy and | 2024 |
| 2024-12-27 | Ethicon Endo-Surgery Inc. | $129 | Research payment | Cash or cash equivalent | Echelon; Endopath Device, Endo-Mechanical | A Multi-Center Evaluation of the ECHELONT 3000 (Next Generation Powered Stapler) in Laparoscopic Sleeve Gastrectomy and | 2024 |
| 2024-12-24 | United Therapeutics Corporation | $17,136 | Research payment | Cash or cash equivalent | REMODULIN Drug, Pulmonary Arterial Hypertension | A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A | 2024 |
| 2024-12-24 | United Therapeutics Corporation | $4,371 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-12-24 | United Therapeutics Corporation | $2,496 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-12-24 | United Therapeutics Corporation | $2,015 | Research payment | Cash or cash equivalent | REMODULIN Drug, Pulmonary Arterial Hypertension | A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A | 2024 |
| 2024-12-24 | United Therapeutics Corporation | $1,913 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-12-23 | GENZYME CORPORATION | $22,550 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Pa | 2024 | |
| 2024-12-23 | Janssen Research & Development, LLC | $20,032 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleu | 2024 |
| 2024-12-23 | GENZYME CORPORATION | $8,876 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Pa | 2024 | |
| 2024-12-23 | GENZYME CORPORATION | $5,384 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Pa | 2024 | |
| 2024-12-23 | Bayer Healthcare Pharmaceuticals Inc. | $512 | Research payment | Cash or cash equivalent | Kerendia Drug, Cardio-renal | BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy a | 2024 |
| 2024-12-20 | Janssen Research & Development, LLC | $9,036 | Research payment | Cash or cash equivalent | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2024 | |
| 2024-12-19 | GlaxoSmithKline, LLC. | $14,021 | Research payment | Cash or cash equivalent | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | 2024 | |
| 2024-12-19 | AstraZeneca Pharmaceuticals LP | $3,555 | Research payment | Cash or cash equivalent | FASENRA Biological, Respiratory | The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do no | 2024 |
| 2024-12-19 | ModernaTX, Inc. | $3,059 | Research payment | Cash or cash equivalent | A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immu | 2024 | |
| 2024-12-19 | Edwards Lifesciences Corporation | $2,826 | Research payment | Cash or cash equivalent | RIGHT-FLOW 2021-13 | 2024 | |
| 2024-12-19 | Galderma Laboratories, L.P. | $965 | Research payment | Cash or cash equivalent | A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With | 2024 | |
| 2024-12-19 | GlaxoSmithKline, LLC. | $178 | Research payment | Cash or cash equivalent | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | 2024 | |
| 2024-12-18 | Merck Sharp & Dohme LLC | $10,500 | Research payment | Cash or cash equivalent | LAGEVRIO Biological, INFECTIOUS DISEASE | A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupirav | 2024 |
| 2024-12-18 | Bolton Medical Inc | $1,690 | Research payment | Cash or cash equivalent | TREO ABDOMINAL STENT-GRAFT SYSTEM Device, ENDOVASCULAR AORTIC REPAIR | TIGER PAS | 2024 |
| 2024-12-17 | Gilead Sciences, Inc. | $1,713 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-12-16 | SANOFI US SERVICES INC. | $21,439 | Research payment | Cash or cash equivalent | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | 2024 | |
| 2024-12-16 | Edwards Lifesciences Corporation | $9,389 | Research payment | Cash or cash equivalent | ALLIANCE 2021-05 | 2024 | |
| 2024-12-16 | Merck Sharp & Dohme LLC | $2,500 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2024 |
| 2024-12-16 | United Therapeutics Corporation | $2,145 | Research payment | Cash or cash equivalent | REMODULIN Drug, Pulmonary Arterial Hypertension | A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A | 2024 |
| 2024-12-13 | Genentech, Inc. | $36,115 | Research payment | Cash or cash equivalent | Phase II dose finding study in prodromal early manifest HD individuals | 2024 | |
| 2024-12-13 | Genentech, Inc. | $36,003 | Research payment | Cash or cash equivalent | Phase II dose finding study in prodromal early manifest HD individuals | 2024 | |
| 2024-12-13 | Genentech, Inc. | $4,589 | Research payment | Cash or cash equivalent | Evaluation of Fenebrutinib in RMS patients | 2024 | |
| 2024-12-13 | Novocure Inc. | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Optune Lua (NovoTTF-200T) Device, Oncology | 2024 | |
| 2024-12-12 | Edwards Lifesciences Corporation | $2,913 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2024 | |
| 2024-12-12 | Edwards Lifesciences Corporation | $1,045 | Research payment | Cash or cash equivalent | ExCEED Trial #2017-18 | 2024 | |
| 2024-12-11 | Amgen Inc. | $3,425 | Research payment | In-kind items and services | IMDELLTRA (AMG757) Biological, Hematology | AMG 757_SCLC_20160323 | 2024 |
| 2024-12-11 | United Therapeutics Corporation | $2,145 | Research payment | Cash or cash equivalent | REMODULIN Drug, Pulmonary Arterial Hypertension | A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A | 2024 |
| 2024-12-11 | PFIZER INC. | $1,434 | Research payment | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | A PHASE 12 OPENLABEL MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEPUP PRIMING DOSES AND LONGER DOSING INTE | 2024 |
| 2024-12-11 | Roche Diagnostics Operations, Inc. | $1,061 | Research payment | Cash or cash equivalent | Elecsys Troponin T Gen 5 STAT Device, Cardiovascular | RD005477 | 2024 |
| 2024-12-11 | AstraZeneca Pharmaceuticals LP | $360 | Research payment | Cash or cash equivalent | LOKELMA Drug, Cardiovascular and Metabolism | Cardiovascular Renal and Metabolism Lokelma Hyperkalemia | 2024 |
| 2024-12-10 | Boston Scientific Corporation | $2,252 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | AGENT IDE | 2024 |
| 2024-12-09 | Medtronic, Inc. | $750 | Research payment | Cash or cash equivalent | ACTIVA PC Device, Deep Brain Neurostimulation | Epilepsy Post-Approval St | 2024 |
| 2024-12-06 | Janssen Scientific Affairs, LLC | $85,000 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-12-06 | AstraZeneca UK Limited | $39,050 | Research payment | Cash or cash equivalent | CALQUENCE Drug, Oncology | Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Pat | 2024 |
| 2024-12-06 | Genentech, Inc. | $26,082 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Ocrelizumab RMS High Dose Study | 2024 |
| 2024-12-06 | Fresenius USA Marketing, Inc. | $23,300 | Research payment | Cash or cash equivalent | Safety of Regional Citrate Anticoagulation (SARCA Study) (SARCA) | 2024 | |
| 2024-12-06 | ModernaTX, Inc. | $11,031 | Research payment | Cash or cash equivalent | A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immu | 2024 | |
| 2024-12-06 | PFIZER INC. | $8,422 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2024 | |
| 2024-12-05 | PFIZER INC. | $52,826 | Research payment | Cash or cash equivalent | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND AN | 2024 | |
| 2024-12-05 | PFIZER INC. | $23,852 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2024 |
| 2024-12-05 | ABBVIE INC. | $20,550 | Research payment | Cash or cash equivalent | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | 2024 | |
| 2024-12-05 | ABBVIE INC. | $11,515 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Sever | 2024 |
| 2024-12-05 | Daiichi Sankyo Inc. | $11,050 | Research payment | Cash or cash equivalent | U31402-A-U103 | 2024 | |
| 2024-12-05 | Cleerly, Inc. | $5,200 | Research payment | Cash or cash equivalent | TRANSFORM | 2024 | |
| 2024-12-05 | Daiichi Sankyo Inc. | $3,000 | Research payment | Cash or cash equivalent | U31402-A-U201 | 2024 | |
| 2024-12-05 | Lilly USA, LLC | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-12-05 | ABBVIE INC. | $2,750 | Research payment | Cash or cash equivalent | Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson s Disease With Motor Fluctuations (TEMPO-3) | 2024 | |
| 2024-12-05 | Daiichi Sankyo Inc. | $2,731 | Research payment | Cash or cash equivalent | U31402-A-U103 | 2024 | |
| 2024-12-05 | ABBVIE INC. | $1,679 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants Wit | 2024 |
| 2024-12-05 | PFIZER INC. | $1,434 | Research payment | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | A PHASE 12 OPENLABEL MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEPUP PRIMING DOSES AND LONGER DOSING INTE | 2024 |
| 2024-12-05 | ABBVIE INC. | $1,250 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2024 |
| 2024-12-05 | ABBVIE INC. | $1,200 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2024 |
| 2024-12-05 | ABBVIE INC. | $850 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2024 |
| 2024-12-05 | ABBVIE INC. | $500 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2024 |
| 2024-12-04 | Merck Sharp & Dohme LLC | $104,860 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX 106 and INBRX-106 in Combination wit | 2024 |
| 2024-12-03 | ABBVIE INC. | $15,000 | Research payment | Cash or cash equivalent | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse | 2024 | |
| 2024-12-03 | Applied Medical Resources Corporation | $9,466 | Research payment | In-kind items and services | Kii Fios First Entry Device, TROCARS PORTS | 2024 | |
| 2024-12-03 | SCYNEXIS, Inc. | $4,300 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Inva | 2024 | |
| 2024-12-03 | Bayer Healthcare Pharmaceuticals Inc. | $4,020 | Research payment | Cash or cash equivalent | Kerendia Drug, Cardio-renal | BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy a | 2024 |
| 2024-12-03 | Tanabe Pharma America, Inc. | $2,452 | Research payment | Cash or cash equivalent | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE EFFICACY, SAFETY, AND TOLERABILIT | 2024 | |
| 2024-12-03 | Gilead Sciences, Inc. | $300 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-12-02 | Janssen Research & Development, LLC | $15,002 | Research payment | Cash or cash equivalent | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2024 | |
| 2024-12-02 | ModernaTX, Inc. | $10,000 | Research payment | Cash or cash equivalent | A Phase 3, Partly Randomized, Observer-blind Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vacci | 2024 | |
| 2024-12-02 | ModernaTX, Inc. | $4,100 | Research payment | Cash or cash equivalent | A Phase 3, Partly Randomized, Observer-blind Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vacci | 2024 | |
| 2024-12-02 | ModernaTX, Inc. | $4,000 | Research payment | Cash or cash equivalent | A Phase 3, Partly Randomized, Observer-blind Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vacci | 2024 | |
| 2024-12-02 | PFIZER INC. | $1,462 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT | 2024 |
| 2024-12-02 | Daiichi Sankyo Inc. | $273 | Research payment | Cash or cash equivalent | DS7300-189 | 2024 | |
| 2024-12-02 | Daiichi Sankyo Inc. | $154 | Research payment | Cash or cash equivalent | DS7300-189 | 2024 | |
| 2024-12-02 | Daiichi Sankyo Inc. | $112 | Research payment | Cash or cash equivalent | DS7300-189 | 2024 | |
| 2024-12-02 | Daiichi Sankyo Inc. | $112 | Research payment | Cash or cash equivalent | DS7300-189 | 2024 | |
| 2024-12-02 | Daiichi Sankyo Inc. | $112 | Research payment | Cash or cash equivalent | DS7300-189 | 2024 | |
| 2024-12-02 | ModernaTX, Inc. | $110 | Research payment | Cash or cash equivalent | A Phase 3, Partly Randomized, Observer-blind Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vacci | 2024 | |
| 2024-12-02 | Daiichi Sankyo Inc. | $86 | Research payment | Cash or cash equivalent | DS7300-189 | 2024 | |
| 2024-12-02 | Daiichi Sankyo Inc. | $62 | Research payment | Cash or cash equivalent | DS7300-189 | 2024 | |
| 2024-12-02 | Daiichi Sankyo Inc. | $50 | Research payment | Cash or cash equivalent | DS7300-189 | 2024 | |
| 2024-12-02 | Daiichi Sankyo Inc. | $46 | Research payment | Cash or cash equivalent | DS7300-189 | 2024 | |
| 2024-12-02 | Daiichi Sankyo Inc. | $46 | Research payment | Cash or cash equivalent | DS7300-189 | 2024 | |
| 2024-12-02 | Daiichi Sankyo Inc. | $46 | Research payment | Cash or cash equivalent | DS7300-189 | 2024 | |
| 2024-12-02 | Daiichi Sankyo Inc. | $46 | Research payment | Cash or cash equivalent | DS7300-189 | 2024 | |
| 2024-12-02 | Daiichi Sankyo Inc. | $46 | Research payment | Cash or cash equivalent | DS7300-189 | 2024 | |
| 2024-12-02 | Daiichi Sankyo Inc. | $46 | Research payment | Cash or cash equivalent | DS7300-189 | 2024 | |
| 2024-12-02 | Daiichi Sankyo Inc. | $46 | Research payment | Cash or cash equivalent | DS7300-189 | 2024 | |
| 2024-12-02 | Daiichi Sankyo Inc. | $46 | Research payment | Cash or cash equivalent | DS7300-189 | 2024 | |
| 2024-12-02 | Daiichi Sankyo Inc. | $46 | Research payment | Cash or cash equivalent | DS7300-189 | 2024 | |
| 2024-12-02 | Daiichi Sankyo Inc. | $46 | Research payment | Cash or cash equivalent | DS7300-189 | 2024 | |
| 2024-12-02 | Daiichi Sankyo Inc. | $46 | Research payment | Cash or cash equivalent | DS7300-189 | 2024 | |
| 2024-12-02 | Daiichi Sankyo Inc. | $46 | Research payment | Cash or cash equivalent | DS7300-189 | 2024 | |
| 2024-12-02 | Daiichi Sankyo Inc. | $46 | Research payment | Cash or cash equivalent | DS7300-189 | 2024 | |
| 2024-12-02 | Daiichi Sankyo Inc. | $46 | Research payment | Cash or cash equivalent | DS7300-189 | 2024 | |
| 2024-12-02 | Daiichi Sankyo Inc. | $44 | Research payment | Cash or cash equivalent | DS7300-189 | 2024 | |
| 2024-12-02 | Daiichi Sankyo Inc. | $29 | Research payment | Cash or cash equivalent | DS7300-189 | 2024 | |
| 2024-12-02 | Daiichi Sankyo Inc. | $6 | Research payment | Cash or cash equivalent | DS7300-189 | 2024 | |
| 2024-12-02 | Daiichi Sankyo Inc. | $4 | Research payment | Cash or cash equivalent | DS7300-189 | 2024 | |
| 2024-12-01 | BioNTech SE | $97 | Research payment | Cash or cash equivalent | BNT327-02 | 2024 | |
| 2024-12-01 | BioNTech SE | $97 | Research payment | Cash or cash equivalent | BNT327-02 | 2024 | |
| 2024-11-28 | Beckman Coulter, Inc. | $275,878 | Research payment | Cash or cash equivalent | CLEAR | 2024 | |
| 2024-11-28 | Beckman Coulter, Inc. | $24,630 | Research payment | Cash or cash equivalent | Scorpion | 2024 | |
| 2024-11-27 | AstraZeneca UK Limited | $60,448 | Research payment | Cash or cash equivalent | IMFINZI Biological, Oncology | durva+monalizumab Solid Tmr-D419NC00001 Phase I/II study MEDI4736 in | 2024 |
| 2024-11-27 | Daiichi Sankyo Inc. | $26,388 | Research payment | Cash or cash equivalent | U31402-A-U103 | 2024 | |
| 2024-11-27 | Daiichi Sankyo Inc. | $10,394 | Research payment | Cash or cash equivalent | U31402-A-U103 | 2024 | |
| 2024-11-27 | CSL Behring | $10,000 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2024 |
| 2024-11-27 | Edwards Lifesciences Corporation | $7,974 | Research payment | Cash or cash equivalent | TRISCEND II Pivotal (2020-05) | 2024 | |
| 2024-11-27 | AstraZeneca Pharmaceuticals LP | $3,098 | Research payment | Cash or cash equivalent | a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat i | 2024 | |
| 2024-11-27 | CSL Behring | $3,000 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2024 |
| 2024-11-27 | CSL Behring | $2,500 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2024 |
| 2024-11-27 | Impulse Dynamics (USA) Inc. | $1,000 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy | 2024 |
| 2024-11-26 | Amgen Inc. | $29,550 | Research payment | Cash or cash equivalent | STARLIGHT P2 LCM Asthma | 2024 | |
| 2024-11-26 | Medtronic, Inc. | $2,725 | Research payment | Cash or cash equivalent | ARCTIC FRONT ADVANCE Device, Ablation | Cryo AF Global Registry | 2024 |
| 2024-11-25 | Gilead Sciences, Inc. | $12,725 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-11-25 | Lilly USA, LLC | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-11-23 | Edwards Lifesciences Corporation | $4,325 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2024 | |
| 2024-11-23 | Edwards Lifesciences Corporation | $865 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2024 | |
| 2024-11-22 | Merck Sharp & Dohme LLC | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-11-22 | E.R. Squibb & Sons, L.L.C. | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | OPDIVO Biological, Oncology | 2024 | |
| 2024-11-22 | ABBVIE INC. | $2,500 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2024 | |
| 2024-11-22 | Nevro Corp. | $1,760 | Grant | Cash or cash equivalent | Senza Device, Spinal Cord Stimulator | 2024 | |
| 2024-11-22 | Medical Device Business Services, Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-11-21 | PFIZER INC. | $64,075 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJE | 2024 |
| 2024-11-21 | Incyte Corporation | $12,750 | Research payment | Cash or cash equivalent | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Part | 2024 | |
| 2024-11-21 | PFIZER INC. | $6,982 | Research payment | Cash or cash equivalent | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND AN | 2024 | |
| 2024-11-21 | Amgen Inc. | $5,585 | Research payment | In-kind items and services | AMG 193 Combo with IDE397 MAT2A | 2024 | |
| 2024-11-20 | ABBVIE INC. | $500 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2024 | |
| 2024-11-20 | Genentech, Inc. | $434 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | Tecentriq plus Avastin Following Curative Resection in Patients at High Risk of Recurrence | 2024 |
| 2024-11-19 | United Therapeutics Corporation | $32,092 | Research payment | Cash or cash equivalent | REMODULIN Drug, Pulmonary Arterial Hypertension | A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A | 2024 |
| 2024-11-19 | Enterra Medical, Inc. | $20,300 | Research payment | Cash or cash equivalent | Navigate | 2024 | |
| 2024-11-19 | ABBVIE INC. | $4,550 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously | 2024 | |
| 2024-11-19 | United Therapeutics Corporation | $4,355 | Research payment | Cash or cash equivalent | REMODULIN Drug, Pulmonary Arterial Hypertension | A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A | 2024 |
| 2024-11-19 | Boston Scientific Corporation | $3,500 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_PI | HI-PEITHO | 2024 |
| 2024-11-19 | United Therapeutics Corporation | $780 | Research payment | Cash or cash equivalent | REMODULIN Drug, Pulmonary Arterial Hypertension | A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A | 2024 |
| 2024-11-15 | Ipsen Biopharmaceuticals, Inc | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Onivyde Drug, Oncology | 2024 | |
| 2024-11-15 | Novartis Pharmaceuticals Corporation | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LUTATHERA Drug, Oncology | 2024 | |
| 2024-11-15 | ARRAY BIOPHARMA INC | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-11-15 | Fresenius Kabi USA, LLC | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Smoflipid Drug, Parental Nutrition | 2024 | |
| 2024-11-15 | Roche Diagnostics Operations, Inc. | $477 | Research payment | Cash or cash equivalent | Elecsys Troponin T Gen 5 STAT Device, Cardiovascular | RD005477 | 2024 |
The latest 200 records of 1,727.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Detroit, MI, county Wayne County, MI, state Michigan; placed by its city name.
| Measure | Place (city or town) Detroit, MI | County Wayne County, MI | State Michigan |
|---|---|---|---|
| Population B01003 | 638,530 | 1,772,259 | 10,077,761 |
| Population, 2020 census P1 | 639,111 | 1,793,561 | 10,077,331 |
| Median age B01002 | 35.2 | 37.9 | 40.2 |
| Under 18 B01001 | 24.8% | 23.6% | 21.2% |
| 65 and over B01001 | 15.1% | 16.6% | 18.6% |
| Households B11001 | 257,998 | 700,591 | 4,076,369 |
| Foreign born B05002 | 6.6% | 10.3% | 7.2% |
| Median household income B19013 | $39,938 | $60,539 | $72,875 |
| Median family income B19113 | $49,398 | $79,522 | $93,357 |
| Per capita income B19301 | $24,594 | $34,906 | $40,735 |
| Poverty rate B17001 | 32.7% | 20.8% | 13.2% |
| Unemployment rate B23025 | 14.0% | 8.7% | 5.7% |
| Civilian labor force B23025 | 268,955 | 828,838 | 5,018,449 |
| Mean commute (minutes) B08013 | 24.8 | 24.7 | 24.2 |
| Bachelor's degree or higher B15003 | 18.1% | 27.6% | 32.4% |
| Housing units B25001 | 329,393 | 801,083 | 4,622,236 |
| Owner-occupied B25003 | 50.3% | 64.8% | 73.2% |
| Renters B25003 | 49.7% | 35.2% | 26.8% |
| Median home value B25077 | $83,900 | $178,500 | $231,600 |
| Median gross rent B25064 | $1,074 | $1,132 | $1,129 |
| White, not Hispanic B03002 | 10.8% | 47.9% | 72.4% |
| Black B03002 | 75.0% | 36.6% | 13.1% |
| Hispanic or Latino B03002 | 8.3% | 6.9% | 5.9% |
| Asian B03002 | 1.7% | 3.7% | 3.4% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Detroit, MI.
Comments